IDYA - IDEAYA Biosciences

-

$undefined

N/A

(N/A)

IDEAYA Biosciences NASDAQ:IDYA IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.

Location: 7000 Shoreline Ct Ste 350, California, 94080-7604, US | Website: www.ideayabio.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.067B

Cash

676.3M

Avg Qtr Burn

-61.9M

Short % of Float

12.32%

Insider Ownership

1.04%

Institutional Own.

-

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Darovasertib Details
Uveal melanoma

Phase 3

Initiation

Darovasertib (IDE196) + crizotinib Details
Solid tumor/s, Metastatic uveal melanoma, Cancer

Phase 2/3

Data readout

Darovasertib Details
Cancer, Ocular melanoma

Phase 2

Data readout

Darovasertib (IDE196) + crizotinib Details
Solid tumor/s, Metastatic uveal melanoma, Cancer, Cutaneous Melanoma

Phase 2

Data readout

IDE397 (MAT2A) Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma, Bladder cancer

Phase 1/2

Data readout

Phase 1/2

Update

IDE849 (SHR-4849) Details
Cancer, Small cell lung cancer

Phase 1

Data readout

IDE397 (MAT2A) + Trodelvy Details
MTAP-Deletion Urothelial Cancer

Phase 1

Data readout

IDE161 +/- KEYTRUDA® (pembrolizumab) Details
Solid tumor/s, Cancer, ER+/HER2- breast cancer, Ovarian cancer, Endometrial cancer

Phase 1

Update

IDE275 (GSK959) Details
Solid tumor/s, Cancer

Phase 1

Initiation

IDE397 (MAT2A) +/- AMG 193 Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

Failed

Discontinued